

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/607,974-Conf. #6971
				Filing Date	June 30, 2003
				First Named Inventor	Ginette Serrero
				Art Unit	1635
				Examiner Name	T. Gibbs
Sheet	1	of	1	Attorney Docket Number	27600-00014-US7

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CVVV	Agrawal et al., "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice," September 1991, Proc. Natl. Acad. Sci. USA. Vol. 88, pp. 7595-7599.	
	CWWW	Chiang et al., "Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms," September 1991, The Journal of Biological Chemistry, Vol. 266 No. 27, pp. 18162-18171.	
	CXXX	Dean and McKay, "Inhibition of protein kinase c- α expression in mice after systemic administration of phosphorothioate antisense oligonucleotides," November 1994, Proc. Natl. Acad. Sci. USA. Vol. 91, pp. 11762-11766.	
	CYYY	Gewirtz et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise," April 1996, Proc. Natl. Acad. Sci. USA. Vol. 93, pp. 3161-3163.	
	CZZZ	Kozarsky and Couture. "Message Therapy: Gene therapy that targets mRNA sequence and stability," 1997, Am. J. Hum. Genet. Vol. 61, pp. 790-794.	
	CAAAA	Scanlon et al., "Oligonucleotide-mediated modulation of mammalian gene expression," 1995, FASEB J., Vol. 9, pp. 1288-1296.	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	11/23/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/